Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients - The European MelSkinTox study.
Jean-Matthieu L'OrphelinJ CassecuelL KandolfC A HarwoodP TookeyMuhammad Hyder JunejoSarah HoganC LebbéZoi ApallaT-M KränkeGiovanni PellacaniD CerasuoloBranko DujovicV Del MarmolA ForschnerClaus GarbeV BatailleJulia Maria ResslerP SollenaA DompmartinKetty PerisBrigitte Drenonull nullPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Our study has characterized the clinical spectrum of cutaneous irAEs, their timing and severity and their relationship with tumour response. Grade I-II cutaneous IrAE are easily managed allowing ongoing anti-cancer treatment. Severe late-onset cutaneous irAE are not uncommon. A dermatologic follow-up helps mitigate the risk of life-threatening adverse events. These findings highlight the importance of onco-dermatologic involvement in management of patients with melanoma receiving immunotherapy.